Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$316.00$316.00derived−97.3% vs Q4 2020 Net Income$2.40M$2.40MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$8,545N/M Operating Incomederived-$373,794N/M Operating Cash Flowderived-$391,296N/M Margins · derivedGross margin-2704.1%−2395.0 pt vs Q4 2020
Operating margin-118289.2%−112341.8 pt vs Q4 2020
Net margin758332.3%+775987.1 pt vs Q4 2020
ended Dec 31, 2021 · filed Apr 14, 2022 · 104 d after period end